Theravance Biopharma(TBPH) - 2022 Q4 - Earnings Call Presentation

Approved incremental $75M to existing $250M program initiated Sept'22, with goal to complete program by end of 2023 Prioritize resource allocation toward ampreloxetine Phase 3 study and YUPELRI® (revefenacin) PIFR-2 study PIFR, peak inspiratory flow rate. AGM, Annual General Meeting – May 2, 2023 ‣ Submit orphan drug designation request in early 2023 ‣ $50M potential milestone for TRELEGY Net Sales of ~$2.86B2 Co-promotion agreement with VIATRISTM (35% / 65% Profit Share) Net sales increased 27% Q4'22 vs. Q ...